Objective-To compare the long term effects of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis.
Introduction
Studies of short term infusions of epoprosteol (prostaglandin 12) in the treatment of Raynaud's phenomenon in patients with systemic sclerosis suggested that the beneficial effects lasted for some weeks.' 2 Recently, in an open trial, we showed that patients' symptoms remained improved during winter with either oral nifedipine3 or short term (three consecutive days) infusions of iloprost (Schering AG), a stable analogue of epoprostenol.4 The present study compares these two treatments when allocated to patients blind and at random.
Method
The trial was performed during the winter of 1986-7. It was a double blind, randomised group comparison of patients receiving intravenous infusions of iloprost and capsules of placebo that matched nifedipine with patients receiving capsules of nifedipine and intravenous infusions of placebo (physiological saline). Blindness of the investigators was ensured by controlling treatment at one centre (Guy's Hospital) and performing clinical and temperature and blood flow assessments separately at two independent departments of another centre (St Bartholomew's Hospital).
Thirty seven patients were recruited from the dermatology clinic. All had well documented systemic sclerosis (American Rheumatism Association criteria)' and Raynaud's phenomenon and appearances typical of systemic sclerosis on capillaroscopy of the fingernail fold. 6 
Results
Of the 37 patients referred for possible inclusion in the trial, 14 were rejected mainly because they had previously taken nifedipine and had felt no benefit or their side effects had outweighed benefit. There was no difference between the patients receiving iloprost and those receiving nifedipine with regard to mean (SE) age (51 (3) years v 53 (3) years) or duration of disease (17 (4) years v 15 (4) years). Three patients were men and these were randomised to receive nifedipine.
Headache, nausea, and vomiting occurred in more than half the patients during the infusion of iloprost but passed off rapidly afterwards. These symptoms appeared to be dose related and were not severe enough to stop the infusion. Though all the patients received the maximum dose of 2-0 ng/kg/min for a short time, the dose was reduced to 1-5 ng/kg/min in 10 patients.
Five patients were unable to tolerate the maximum dose of nifedipine, and three others withdrew because of side effects-two with headache by week 8 and one with peripheral oedema after 12 weeks. One patient in each group withdrew for social reasons. The one who was randomised to receive iloprost withdrew immediately after baseline assessment, and the one receiving nifedipine withdrew after eight weeks. During the trial there was no change in haematological or biochemical variables that could be attributed to either drug. Table I shows that the mean number, duration, and severity of attacks of Raynaud's phenomenon was reduced by both drugs. Half of the patients in each group thought that their symptoms had improved, and one patient in each group thought that they had become worse. Table II shows that both drugs considerably reduced the mean number of skin lesions. Assessments of baseline blood flow were slightly higher for those receiving nifedipine than for those receiving iloprost. Consequently, mean changes from baseline were used to compare the two treatments. Figure 1 shows that digital blood flow at all time points was increased from baseline with iloprost and significantly reduced with nifedipine at weeks 4 and 8. The overall difference between the treatments was significant. Microcirculatory flow (fig 1) at all times was increased from baseline with iloprost, and the increase was significant at week 8 Figure 2 shows that mean blood pressure was reduced with both regimens, although the reduction was greater with nifedipine. This was associated with an increase in blood flow in the forearm and a significant reduction in peripheral vascular resistance in the forearm (fig 2) .
Discussion
Though the values were typical of those found in systemic sclerosis, a difference in the blood flow measurements was observed between patients receiving iloprost and those receiving nifedipine, but this was possibly owing to the small number of patients. Thus in the analysis the relative change from baseline was used to compare the two treatments. One other possible source of bias was the exclusion from entry into the study of patients known to be intolerant to nifedipine. Despite the exclusion three of the 11 patients in this group dropped out during the trial by week 12 because of side effects at the lowest dose (30 mg daily).
In contrast, side effects with iloprost occurred only during the infusion and were those usually associated with infusion of prostanoids-that is, headache and nausea. They were not severe enough to warrant interruption of the infusion and stopped shortly after the infusion was stopped. Most of the patients, however, were able to tolerate the maximum dose (2 ng/kg/min), though not always for the full 15 minutes. Clearly care should be taken to start the infusion with a small dose and to increase the dose incrementally and slowly, regarding minor side effects as an indication for slight reduction. Similarly, side effects with nifedipine may be avoided by starting with a low dose, 5 mg three times daily, and increasing the dose incrementally. Both regimens were beneficial as measured by the rate of healing of digital lesions and reduction in the number, duration, and severity of painful attacks of Raynaud's phenomenon.
With the exception of our previous trial of nifedipine in patients with systemic sclerosis3 it is difficult to compare the results of this investigation with results of other studies of nifedipine in the treatment of Raynaud's phenomenon. " '7 These investigations were, with one exception,'6 short (two to three weeks) and they recorded only one objective measurement of blood flow, which in some instances, as commented on by Rustin et al,'8 was obtained after unreasonable stimuli." In addition most of them included patients with Raynaud's disease, in which vasospasm may be less severe and structural change in the digital vessels is slight or absent. Also when patients with systemic sclerosis were included any decreases in the numbers of digital lesions were not recorded.
The difference between the drugs may be that nifedipine is a general vasodilator with little effect on damaged digital vessels, whereas iloprost produces specific effects that increase blood flow in these vessels. This is suggested by the greater fall in mean blood pressure and the more pronounced enhancement of blood flow in the forearm and fall in peripheral vascular resistance that occur with nifedipine compared with iloprost ( fig 2) . The general systemic effect ofnifedipine may be associated with the fall in digital blood flow and the virtually undetectable change in microcirculatory flow (fig 1) , which may be due to reflex sympathetic stimulation caused by systemic vasodilatation and the fall in mean blood pressure."' This may explain the reduction in digital blood flow and increased peripheral vascular resistance described by Lindsey et al when they used nifedipine 60 mg daily in patients with sclerosis.20 Considering the necessity for an intact endothelium in the relaxation of arterial smooth muscle21' it may be that the digital vessels in systemic sclerosis, in which endothelial cells are characteristically abnormal, may be most susceptible to vasoconstriction.
Digital lesions, however, healed with both regimens, suggesting that the beneficial effect of nifedipine may be brought about by a mechanism other than enhancement of blood flow-for example, alteration of mechanisms in local tissue, so protecting against the response to cold.2' Also it has been shown that nifedipine enhances thrombolysis,24 an effect which may be important in disease where this activity is known to be depressed.2526
Mean blood pressure Healing of the endothelial lesion accompanied by the local release of vasodilatory substances-for example, epoprostenol and nitric oxide (endothelium derived relaxing factor) -may be responsible for the enhanced digital flow that persists for weeks after infusion of iloprost. Interestingly, the effect of three consecutive daily infusions of iloprost was to increase microcirculatory blood flow (fig 1) at week 4, which became maximal at week 8. This suggests a process of continuous repair, an effect that was maintained for a further four weeks by a single infusion but was no longer evident at week 16 Blood pressure has been suggested as one link between the intrauterine environment and risk of cardiovascular disease. 6 We have therefore examined the relations among blood pressure, pulse rate, and intrauterine influences, as measured by birth weight, gestational period, mother's height, and mother's blood pressure. To do this we have used data from two large national samples, one of children aged 10 and another of adults aged 36.
We used geographical comparisons within England and Wales to examine the relation between intrauterine influences and cardiovascular disease. We compared geographical variations in mothers' heights and blood pressures, and in the birth weights of their children, with differences in cardiovascular mortality.
Subjects and methods
1970 Cohort-Roughly 97 5% of all births in Great Britain during one week in April 1970 were included in the British births survey.79 Information recorded at around the time of birth included birth weight, gestational period, and mother's blood pressure at first attendance at the antenatal clinic. Social class at birth was derived from father's occupation. Surviving children were followed up at 10 years when they were examined by clinical medical officers. Their heights, weights, blood pressures, and pulse rates were measured by standardised procedures. Mothers' heights were also recorded. Blood pressure was measured towards the end of the examination by using a sphygmomanometer. The cuff size, which was recorded, was sufficient to encircle the upper arm completely and cover two thirds of its length. Diastolic
